Stock Rating Downgrade
The Value Trend Rating for Neurocrine Biosciences Inc (NASDAQ: NBIX) weakened in the last week from C to D reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.
Recent Price Action
Neurocrine Biosciences Inc (NASDAQ: NBIX) stock increased 1.6% on 1/10/25. The shares closed at $140.90. Trading volume in this advance was normal. The stock has been weak relative to the market over the last nine months but has risen 3.2% during the last week.
Current PriceTarget Research Rating
Neurocrine Biosciences has a current Value Trend Rating of D (Negative). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing inconsistent signals. Neurocrine Biosciences has a neutral Appreciation Score of 50 but a poor Power Rating of 28, and the Negative Value Trend Rating results.
Be the first to comment